Skip to main content

Daiichi Sankyo Ltd(DSKYF)
OTC US

Today's Change
Delayed Last Update

Daiichi Sankyo Ltd

Sectors & Indices

Sector
Industry
Employees

    Profile

    Daiichi Sankyo Co Ltd was founded on September 28, 2005. The Company is engaged in the research, development, manufacture, sale and marketing of pharmaceutical products. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Memary and Donepezil for the treatment of alzheimer's disease; Nexium for treating reflux esophagitis; Inavir, an anti-influenza treatment product; ActHIB, a haemophilus b conjugate vaccine; and Loxonin S, an analgesic and anti-inflammatory drug; Denosumab, an antibody for the treatment and prevention of various bone disorders; and Edoxaban, an oral anticoagulant product. The Company also markets therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome, and metastatic melanoma.

    Key Executives

    NameTitle
    Information not available.